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TECHNICAL NOTE
Plasma exchange with a rotating filter
ANDRE A. KAPLAN and SUSAN E. HALLEY
Division of Nephrology, Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut, USA
Plasma exchange with a rotating filter. We have modified a rotating
filter system to provide therapeutic plasma exchange. Seventeen pa-
tients underwent 188 treatments. Blood flows to the filter ranged from
75 to 100 mI/mm; mean filtration fraction was 64 1% L ;., N — 188).
Mean plasma removal rate per treatment was 40.2 0.6 mI/mm; net
plasma removed per treatment was 3231 53 ml (N 188); mean
treatment time was 83 2 minutes (N = 188). Mean percent decline in
platelet count was 15 4% (N = 46). Immunoglobulin kinetics were
evaluated in order to validate our method of treatment prescription, The
apparent volume of distribution (AVD) for each immunoglobulin class
was compared to our estimate for plasma volume (EPV). The fraction
AVD/EPV for IgG was 0.97 0.04 (N = 14), for IgA was 0.87 0.04(N = 13) and for 1gM was 0.96 0.3 (N = 26). Use of the EPV allowed
for accurate prediction of treatment results. Correlation between ex-
pected and actual decline in serum levels revealed an r value of 0.86 for
IgG (P = 0.0002), 0.88 for IgA (P = 0.0001), and 0.57 for 1gM (P <
0.003). We conclude that a rotating filter system can provide a highly
efficient means of plasma exchange. The use of a simplified method of
estimating plasma volume allows for a reliable prediction of treatment
results.
Therapeutic plasma exchange is currently performed by two
techniques the older method utilizes a blood cell separator
which fractionates the plasma by centrifugation; and a more
recent technique employs highly porous hollow fibers to sepa-
rate the plasma by a process of filtration. Each of the two
techniques has its own advantages and drawbacks [1]. The
centrifugation technique is most often performed using antecu-
bial access, allows removal of specific cell types (apheresis) and
is generally available anywhere blood banking services exist.
The procedure, however, is rather slow, often requiring two to
three hours for a single plasma volume exchange, uses large
volumes of citrate anticoagulation and has an almost obligatory
platelet loss (30 to 50%) [2, 3]. The membrane based technique
is generally more efficient and results in a more modest (8%)
decline in platelet '-ount [3]. The filters, however, are expensive
($100 to $150/filter) and efficient operation of the system often
requires large bore blood access, such as with a double-lumen
femoral catheter.
The recent development of rotating filter technology has led
to the availability of an automated device for plasma collection
[4]. The device uses an inexpensive ($35) rotating membrane in
a single needle, discontinuous flow manner. The results ob-
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tamed during donation procedures (500 to 800 ml of plasma)
[4—7], suggested to us that the system might be particularly
efficient for use during therapeutic plasma exchange. Using a
modified system designed to allow for double needle, continu-
ous flow operation, our previous in vitro studies have demon-
strated the feasibility of using this rotating filter for removal of
therapeutically important molecules (gamma globulins, Beta-
lipoprotein, etc.) [8]. In that same publication, we reported
promising results of our preliminary in vivo application. We
now report on a one year clinical experience using a rotating
filter for therapeutic plasma exchange.
Methods
Patient selection
During the 12 month period from January, 1988 to January,
1989, patients admitted to the John Dempsey Hospital for
plasma exchange were offered treatment with our modified
system. Indication for plasma exchange was made by the
patient's consulting physician. The study was approved by the
institution's Investigational Review Board. All patients signed
informed consent.
Technique and equipment
Plasma removal was with an Autopheresis C plasma collec-
tion device (Fenwall, Deerfield, Illinois, USA) designed to
provide a filter rotation of 3600 cpm. The Plasmacell filter
(model 4R2252, Fenwall) has a polyamide-based cylindrical
membrane with a surface area of 70 cm2 and a pore size of 0.8
microns (Fig. 1). The original tubing was modified to allow for
double needle, continuous flow operation. The operating trans-
membrane pressure was increased by placing the collection bag
at the base of the machine. Blood flows to the Autopheresis C
are controlled by a pressure-sensitive computor program and
are restricted to a range of 60 to 100 ml/min. Blood access was
with bilateral antecubital vein cannulation with 16 guage nee-
dles, placement of a double-lumen femoral catheter (model
SC-200l, Shiley Inc., Irvine, California, USA, or a model
13794, Quinton Instruments Co, Seattle, Washington, USA) or
with 16 guage needles placed in an arterio-venous fistula. Five
percent albumin solution (Baxter Healthcare Corp., Glendale,
California, USA) was given in a one to one volume replacement
and was propelled by an occlusive blood pump (model RS7800,
Minntech, Minneapolis, Minnesota, USA). Anticoagulation
was with Formula B citrate solution (Fenwall) at either 6 or 8%
volume ratio. In general, calcium replacement was with one 10
ml ampule of 10% calcium chloride solution administered over
15 to 30 minutes using a Harvard mini-infusion pump (CR Bard
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AVD = total amount removed/net change in serum levels
and was calculated as follows:
[(concentration in plasma collection bag)
x (volume of collection)]/[( pretreatment serum value
— post-treatment serum value)]
Fig. 1. Rotating filter for plasma separation. Blood entering the top of
the filter assembly travels down the space between the rotating cylin-
drical membrane and the outer plastic casing (stationary cylinder).
Plasma passes through the membrane and flows from the filter's hollow
central core.
Inc. North Reading, Massachusetts, USA). If treatment time
was considerably longer than 90 minutes, a second 10 ml
ampule of calcium was infused.
Laboratory evaluation
Prothrombin times (PT) and partial thromboplastin times
(PTT) were evaluated using Organon Teknica reagents on a
Coag-A-Mate X2 instrument. Complete blood counts (CBC),
including hematocrit and platelet counts were performed on a
model 880 Coulter Counter. Immunoglobulin measurements
were performed by rate nephelometry on a Beckman Auto-
mated Immunochemistry Analyzer (Beckman Instruments Inc.,
Brea, California, USA).
Calculations
Estimated plasma volume was calculated using the formula:
EPV = [0.065 x wt(kg)] — Hct%
The amount of plasma to be exchanged was determined by
estimating the percent decrease in plasma levels using the
formula:
X — Ve/AVD)
where X represents the final plasma concentration, X0
represents the initial concentration, Ye represents the volume
exchanged and AVD equals the apparent volume of distribution
for the substance to be removed [9]. The sieving coefficients are
assumed to be one, as we have previously documented [8].
When removing a substance whose apparent volume of distri-
bution equals one plasma volume, this formula will predict a
63% decline in serum levels after a single plasma volume
exchange. Apparent volume of distribution (AVD) for several
serum proteins was determined by measuring pre- and post-
treatment serum values and the total amount removed in the
plasma collection bag. Calculation of the apparent volume of
distribution was with the formula:
Filtration fractions (FF) were estimated by dividing the
amount of plasma removed by the amount of plasma delivered
to the filter. The amount of plasma delivered was estimated by
determining the average blood flow, as monitored during the
entire treatment, and decreasing this figure by the percent
hematocrit. The values used were adjusted for the addition of
either a 6 or 8% volume of citrate solution.
Statistical analysis was performed by simple regression with
a Stat View 512+ statistical package from Macintosh. Means
are given with their standard errors (± su). The null hypothesis
was rejected at P < 0.05.
Results
Technique
Seventeen patients underwent 188 treatments. Blood access
was provided by antecubital veins (N 147), double-lumen
femoral catheters (N 38) or an arterio-venous fistula (N = 3).
Blood flows ranged from 75 to 100 mllmin. Mean filtration
fraction was 64 1% (range 34 to 86, SE, N 188). Mean
plasma removal rate per treatment, irrespective of blood ac-
cess, was 40.2 0.6 mI/mm (range 21 to 60; N 188) with a
value of 40.3 0.7 mI/mm (range 21 to 60) for antecubital
access (N = 147) and 39.5 1.2 ml/min (range 31 to 56) for
femoral catheters (N = 38). Mean pretreatment hematocrit was
35.5 0.4% (range 20 to 44). Net plasma removed per treat-
ment was 3231 53 ml (N = 188). Mean volume of citrate
infused into the patient per treatment was 264 9 ml (range 75
to 500). Mean treatment time was 83 2 minutes. Of 141
outpatient procedures, 134 were performed with antecubital
access.
Treatment prescription
In six patients, monitoring of immunoglobulin levels was
considered clinically useful. Serum levels were taken prior to
and immediately after each treatment. These values were
compared with the net amount removed in order to calculate the
apparent volume of distribution (AVD; see calculations). A
total of 27 treatments were monitored in this manner. When the
AVD for each immunoglobulin class was divided by our esti-
mate for plasma volume (EPV), the fraction AVD/EPV for IgG
was 0.97 0.04 (N = 14, SE), for IgA was 0.87 0.04 (N =
13), and for IgG was 0.96 0.03 (N = 26). The highly significant
correlation between these two values is demonstrated in Figure
2. Prior to each treatment, the expected percent decline for
each immunoglobulin class was estimated using first order
kinetics and substituting our calculated EPV for the value of
AVD required in the formula (Calculations in Methods section).
The correlations between the actual percent decline and the
predicted values are demonstrated in Figure 3.
162 Kaplan and Halley: Plasma exchange with a rotating filter
5
4
3
2
0
0 1 2 34
r = 0.96, P < 0.0001
y = 1.51x — 1.35
5
4
3
2
0
0 1 2 3 4 5
r = 0.98, P < 0.0001
V = 1.55x — 1.71
5
4
3
2
1
0
0 1 2 34 5
r = 0.83, P < 0.0001
y = 1.39x — 1.09
Estimated plasma volume
liters
Fig. 2. Correlation between the measured apparent volume of distri-
bution (AVD) and the estimated plasma volume (EPV). Each symbol
represents a different patient. For calculations see text.
Coagulation studies
For the first three months of the study, all patients were
evaluated for changes in coagulation status including hemato-
crit, platelet count, prothrombin time (PT) and partial throm-
boplastin time (PTT). A total of 46 treatments in eight patients
were evaluated in this manner. A comparison of pre- and
post-treatment blood values revealed a mean 10 1% decline in
hematocrit and a 15 4% decline in platelet count (N = 46).
There was no evidence for substantial extracorporeal blood loss
nor any evidence for significant hemolysis. The effect of plasma
exchange on the coagulation cascade was highly dependent on
treatment scheduling. For 31 treatments before which there had
been no prior treatment for at least one week, a comparison of
pre- and post-treatment coagulation tests revealed an increase
in the prothrombin time (PT) from 9.6 0.3 seconds to 12.6
0.4 seconds and an increase in the partial thromboplastin time
(PTT) from 28.1 0.4 seconds to 55.4 4.9 seconds. After
treatment, we found a substantial improvement within several
hours. After a series of daily exchanges the coagulation status
was more profoundly affected after each treatment, but there
was generally a return towards normal by the next day.
Complications
Technical considerations. Our original tubing modification
resulted in some minor blood leaks, and the problem was
completely eliminated when the manufacturer supplied us with
modified tubing assembled in the factory. Except for plasma
collected from patients with hyperbilirubinemia, the plasma
removed was clear, with no visual evidence for hemolysis.
Random sampling of collected plasma from five treatments
revealed plasma hemoglobin levels ranging from 0 to 10 mgldl.
Only one of the Plasmacell filters developed an observable
blood leak. The filter was changed with no clinical sequela.
Clinical considerations. There were no significant adverse
effects which were the result of the treatment procedure. In
particular, hypotension, shock, respiratory distress or any sign
of anaphylaxis were not observed. In the early phases of the
study several patients experienced perioral and distal extremity
parasthesias which were successfully treated with calcium
infusion. As a result, our original protocol was modified to
include a standard calcium infusion during each treatment. The
only significant complication was an iliac vein thrombophiebitis
and staphyloccocal septicemia related to a femoral catheter
which was kept in situ for four days. The patient was success-
fully treated with antibiotics and anticoagulation.
Discussion
The results of this study, in a substantial number of proce-
dures, clearly demonstrate the efficiency of a rotating mem-
brane system for providing rapid plasma exchange. Within the
range of blood flows allowable by the machine's programming
(60 to 100 mllmia), we found no demonstrable difference in the
rapidity of plasma removal when antecubital access was com-
pared to femoral access. As anticipated from the results of in
vitro testing, [10—12], Taylor vortices created by the rotating
filter allowed for very high filtration fractions without mem-
brane plugging (Fig. 4), thus yielding a highly efficient treatment
despite the relatively modest blood flows obtainable from
antecubital access.
With the desire to optimize the procedure, we were con-
fronted with several choices concerning treatment prescription
and patient management. In general, these issues relate to all
methods of performing plasma exchange.
I. Treatment prescription
We have chosen a rather simplified method to estimate
plasma volume (Calculations). The value of this calculation is
most evident in prescribing the amount of plasma to be ex-
changed per treatment. Although there is a significant extravas-
cular pool of the immunoglobulin classes, approximately 60%
for IgG and IgA and 20% for 1gM [13], radioisotopic studies
demonstrate a daily exchange of only 25% between the extra
and intravascular compartments [14]. Thus, during a one to two
hour procedure, only 1 to 2% of the extravascular pooi will
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Fig. 4. Schematic representation of Taylor vortices created by mem-
brane rotation. The blood follows a helical pathway, spiralling down-
ward around the rotating membrane. Adapted from references 10—12.
enter the intravascular space, lending support to the aforemen-
tioned use of first order kinetics.
If immunoglobulin removal during plasma exchange is limited
to the plasma space, then the apparent volume of distribution
(AVD) should closely approximate the patient's plasma vol-
ume. Thus, we validated our estimate for plasma volume (EPV)
by comparing it to the measured AVD for each immunoglobulin
class. As demonstrated in Figure 2, the correlation between
these two estimates for plasma volume was highly significant.
Thus, our calculated EPV is a satisfactory estimate for the AVD
Table 1. Observed and predicted decline in anti-acetylcholine
receptor (AChR) antibody during treatment for myasthenia gravis
Pre- Post-
RX RX Ye EPV % Decline
Date nmols/liter liters Ve/EPV Actual Predicted
3/23 5.6 1.5 4 2.8 1.43 73 76
3/24 2.4 <Q5a 4 2.9 1.38 79 75
3/25 <0.5 <0.5 4 2.9 1.38 NA 75
4/12 6.9 3.7 12b 2.8 0,41 46b 35
4/13 5.9 1.0 5 2.8 1.79 83 83
Abbreviations are: Ve, volume exchanged; EPV, estimated plasma
volume; NA, not applicable, due to the unmeasureable levels. Predicted
values were obtained using first order kinetics and assuming the
apparent volume of distribution of the antibody to be equal to the EPV
(Methods).
This value was considered to be 0.5 for purpose of calculation
b This procedure was terminated prematurely due to access diffi-
culties; large amounts of saline flushes may have contributed to the
measured decline in post-treatment levels.
for this value in the determination of first order kinetics
(Calculations). Our experience with this method of treatment
prescription found it to yield a reasonably reliable prediction of
the actual decline in plasma levels, not only for entire immu-
noglobulin classes (Fig. 3), but also for a specific autoantibody
(Table 1).
Despite the apparent accuracy of this method of treatment
prescription, it should be used with caution in patients with
macroglobulinemia in whom large amounts of 1gM polymers
can lead to a significantly enhanced viscosity and a resulting
increase in plasma volume [15]. In this case, an estimation of
plasma volume can be determined by calculating the apparent
volume of distribution for 1gM at the conclusion of the first
treatment. In our sole patient with macroglobulinemia, this
calculation was found to correlate well with a determination of
plasma volume by isotopically labeled albumin (AVD of 1gM
was 6.9 liters vs. 6.7 liters by isotopic study).
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Fig. 3. Immunoglobulin kinetics as a result of plasma exchange. Correlation between the predicted and actual percent decline in serum levels.
Predicted values (solid line) were determined using first order kinetics and assuming the apparent volume of distribution (AVD) to be equal to the
estimated plasma volume (EPY). The abscissa represents the value of Ye/AYD or, in this case, Ve/EPV (Calculations in Methods section), where
Ye equals the volume exchanged. The ordinate represents the final serum concentration in terms of percent of initial concentration. Correlation
between the actual decline and predicted decline in serum values revealed an r value of 0.86 for IgG (N = 14, P = 0.0002), 0.88 for IgA (N = 13,
P = 0.0001) and 0.57 for 1gM (N = 26, P < 0.003). Several of the 1gM levels were extremely low, at a point where measurements are less accurate.
of each immunoglobulin class and, as such, can be substitued Of note is that our estimate of plasma volume involves
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consideration of the patient's hematocrit, in contrast to many
previous publications in which treatment volumes are described
in terms of mi/kg, with no regard for hematocrit. This consid-
eration is of a substantial nature, since a difference in hemato-
crit from 45 to 25% leads to a 36% increase in the calculated
plasma volume in a 70 kg patient and a 45% increase in a 100 kg
patient. Thus, many of the previously published studies at-
tempting to determine the usefulness of plasma exchange are
extremely difficult to interpret since the efficiency of immuno-
globulin removal can not be accurately assessed.
With the above considerations in mind, our approach to
treatment prescription was as follows: If the substance to be
removed was measurable by reliable quantitative means, such
as with a specific immunoglobulin or immunoglobulin class,
then the treatment was designed to maintain a time averaged
lowering of that substance using the above mentioned kinetic
formula and taking into account the substance's rate of increase
post-procedure. If the treatments were to be performed without
identification of the offending agent, then empiric treatment
schedules, gleaned from the literature, were incorporated.
2. Choice of access
Due to difficulties with post-treatment hemostasis, there is a
distinct advantage to using antecubital vein access. Although
the Autopheresis C is programmed to operate with blood flows
as low as 60 mI/mm, in some patients, even this modest flow is
unobtainable. In the in-hospital setting, where repetitive treat-
ments are to be performed over a short period of time, the
placement of a double lumen catheter was found to be useful in
providing reliable blood flows. Unfortunately, this practice was
also responsible for our only serious complication. In patients
who would benefit from repetitive treatments in an outpatient
setting, we initiated a program of hand exercises which was
successful in ameliorating antecubital blood flows in every case,
usually within one to two weeks.
3. Replacement fluid
Previous reports have identified the use of plasma containing
solutions, such as fresh frozen plasma (FFP), to be the major
risk factor for the development of anaphylactic reactions during
plasma exchange [16, 17]. In a recent report of the combined
Canadian experience of 1985, encompassing 5235 treatments,
all the serious complications were associated with the use of
these solutions [17]. Furthermore, the large volumes of FFP
required (4 to 5 units per liter) and the small, but real risk of
hepatitis per unit [18, 191 would make repetitive use of this
option virtually certain to lead to infection. In contrast, there is
general agreement in the literature on the safety of albumin
replacement and we believe that our virtually exclusive use of
this solution (182 of 188 treatments) accounted for the absence
of anaphylactic reactions. The major drawback to albumin is
the resulting coagulopathy post-procedure. Despite this coagu-
lopathy, the only hemorrhagic complications encountered were
related to the removal of a large bore catheter and the use of an
arterio-venous fistula.
The above arguments notwithstanding, in certain situations
the use of FFP may be required since its administration may be
the basis for clinical improvement, as may be the case with
thrombotic thrombocytopenic purpura ('FTP) [201.
Table 2. Calcium kinetics with and without supplemental infusion
Total calcium
Serum Total Replace- Net
Pre- Post- Plas- re- Supple- ment bal-
no.
Rx Rx ma moved menta fluidb ance
mg/dl mg
No 2 8.6 7.1 7.4 235 — 87 —148
supplement
3
3
8.9 6.9 7.4
9.5 8.2 7.6
235
242
—
—
87
87
—148
—155
With 2 9.3 9.2 8.7 261 273 87 + 99
supplement
3 9.4 9.0 8.8 280 273 87 + 80
Abbreviation is: Rx, treatment. To convert mg/dl to mEq/liter, divide
by 1.95, to convert mg to mEq, divide by 19.5. All treatments involved
3 liter exchanges.
a 10 ml ampule of 10% CaCl2b 5% albumin solution with measured calcium concentration of 2.9
mg/dl
4. Citrate toxicity and calcium replacement
Plasma exchange using citrate has been associated with a 2 to
9% incidence in perioral and distal extremity parathesias [3, 17].
Citrate infusion may be in the form of anticoagulation for the
system or as a result of large volumes of citrated FFP. Although
felt to be secondary to a decrease in ionized calcium, previous
reports have suggested that prophylactic supplementation of
calcium did not lower the incidence of this complication, but
actual calcium supplementation was either not reported or was
difficult to assess [17, 21]. This is in sharp contrast to our
experience, in which supplemental calcium infusion has virtu-
ally eliminated the problem. In two patients, in whom repetitive
treatments were to be performed, calcium kinetics were evalu-
ated (Table 2). Without supplemental replacement there was a
substantial loss of calcium. With supplementation, the net
balance becomes positive.
Our protocol involved the prefilter dilution of blood with
either a 6 or 8% volume ratio of formula B citrate solution. This
solution contains 73 mmole of citrate and 150 mEq of sodium
per liter. This concentration of citrate, when metabolized to
bicarbonate, will yield a net 219 mEq of bicarbonate per liter.
Thus, we were pleased with the modest infusion of citrate
required during the treatments (mean 264 9 ml/RX). None-
theless the risk of alkalemia persists, especially in patients with
renal failure who are receiving FFP replacement [221.
5. Post-procedure anticoagulation
As described above, the exclusive use of albumin as a
replacement solution results in a significant post-procedure
coagulopathy. The results of our study, revealing a 31% increase
in PT and a 97% increase in PIT, is in excellent agreement with a
previous study, using slightly larger exchange volumes (4 liters), in
which PT increased by 50% and PU by 106% [2]. Also in
agreement with this previous study is our limited data on the
immediate post-procedure period, where we found a substantial
spontaneous improvement after several hours.
The 10% decline in post-treatment hematocrits merits com-
ment. As mentioned above, we could not document any sub-
stantial extracorporeal blood loss during the procedure, neither
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Table 3. Drug removal dunng plasma exchange
Serum
levels
Pre- Post-
Total
amount Ve/(EPV) AVD
Drug Rx Rx removed liters
Vitamin B12 jxg/liter 396 197 890 g 31(3.4) 4.5
Phenytoin mg/liter
total 11 8 29 mg 3/(2.3) 10
free 0,9 0.6
Phenobarbital mg/liter 17 11
1.9mg
45 mg
3/(2.3)
31(2.3)
6
8
Abbreviations are: Rx, treatment; Ve, volume exchanged; EPV,
estimated plasma volume; AVD, apparent volume of distribution (Cal-
culations).
from frank bleeding at the access sites, nor from retained blood
in the filter or tubing set. Furthermore, there was no visual or
measurable evidence for significant hemolysis. Thus, we are
inclined to agree with the conclusions of Chopek and McCul-
logh, who also documented a 10% decline in post-treatment
hematocrits [23]. After reviewing results from treatments with
varying amounts of both FFP and albumin, these authors
concluded that the relatively hyperoncotic nature of the 5%
albumin solution resulted in an intravascular dilution of the
measured hematocrit. This dilution effect could also be partially
responsible for the small decline in post-treatment platelet
counts.
6. Drug dosing
There is little information concerning the removal of thera-
peutic agents by plasma exchange [24—26]. Our data concerning
drug kinetics are listed on Table 3. Until more information is
available, when possible, a daily dose of medication should be
given post-procedure.
Summary and conclusion
A rotating filter system was modified to provide therapeutic
plasma exchange. Experience with 188 procedures has demon-
strated that the system can be useful in providing a highly
efficient treatment. Mean plasma removal rate was 40 mllmin
despite the extensive use of antecubital access. This efficiency
was most notable in the outpatient setting. The only significant
complication was related to vascular access.
Our study of immunoglobulin kinetics suggests that a simple
estimation of plasma volume can allow for a reasonably accu-
rate prediction in treatment results. This accuracy is not present
in many previously published studies attempting to evaluate the
usefulness of plasma exchange.
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